125 related articles for article (PubMed ID: 38224050)
1. Pharmacokinetics, metabolism, excretion and safety of iruplinalkib (WX-0593), a novel ALK inhibitor, in healthy subjects: a phase I human radiolabeled mass balance study.
Bian Y; Ma S; Yao Q; Hu T; Ge M; Li H; Zheng S; Gu Z; Feng H; Yu Z; Huang C; Zhang H; Zhao L; Miao L
Expert Opin Investig Drugs; 2024 Jan; 33(1):63-72. PubMed ID: 38224050
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT).
Shi Y; Chen J; Zhang H; Zhang Z; Zhang Y; Wang Z; Zhang S; Zhao J; Liu C; Wang X; Zhao Y; Hu C; Yang L; Hao X; Wang L; Liu Y; Yu Y; Zhao J; Wang M; Zhang L; Sun S; Hu Y; Gu K; Hang X; Shan J; Zhang Y; Tan B; Yang W; Yang R; Si M; Geng H; Li H; Kang X
BMC Med; 2023 Feb; 21(1):72. PubMed ID: 36829154
[TBL] [Abstract][Full Text] [Related]
3. Mass balance, metabolic disposition, and pharmacokinetics of [
Zhou S; Liu W; Zhou C; Zhang L; Xie L; Xu Z; Wang L; Zhao Y; Guo L; Chen J; Ding L; Mao L; Tao Y; Zhang C; Ding S; Shao F
Cancer Chemother Pharmacol; 2020 Dec; 86(6):719-730. PubMed ID: 33044566
[TBL] [Abstract][Full Text] [Related]
4. Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE).
Shi Y; Chen J; Yang R; Wu H; Wang Z; Yang W; Cui J; Zhang Y; Liu C; Cheng Y; Liu Y; Shan J; Wang D; Yang L; Hu C; Zhao J; Cao R; Tan B; Xu K; Si M; Li H; Mao R; Li L; Kang X; Wang L
J Thorac Oncol; 2024 Jan; ():. PubMed ID: 38280448
[TBL] [Abstract][Full Text] [Related]
5. Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer.
Yang Y; Zheng Q; Wang X; Zhao S; Huang W; Jia L; Ma C; Liu S; Zhang Y; Xin Q; Sun Y; Zheng S
Invest New Drugs; 2023 Apr; 41(2):254-266. PubMed ID: 37036582
[TBL] [Abstract][Full Text] [Related]
6. Iruplinalkib: First Approval.
Keam SJ
Drugs; 2023 Dec; 83(18):1717-1721. PubMed ID: 38008856
[TBL] [Abstract][Full Text] [Related]
7. Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial.
Shi Y; Fang J; Hao X; Zhang S; Liu Y; Wang L; Chen J; Hu Y; Hang X; Li J; Liu C; Zhang Y; Wang Z; Hu Y; Gu K; Huang J; Zhang L; Shan J; Ouyang W; Zhao Y; Zhuang W; Yu Y; Zhao J; Zhang H; Lu P; Li W; Si M; Ge M; Geng H
Signal Transduct Target Ther; 2022 Jan; 7(1):25. PubMed ID: 35087031
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects.
Darwish M; Nunez R; Youakim JM; Robertson P
Clin Drug Investig; 2024 Jan; 44(1):21-33. PubMed ID: 38017349
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, mass balance, and metabolism of [
Ma S; Wang X; Yan S; Miao L; Wan X; Ding D; Yu D; Diao X; Wang X; Zhang H
Cancer Chemother Pharmacol; 2024 Mar; ():. PubMed ID: 38507062
[TBL] [Abstract][Full Text] [Related]
10. Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
Reif S; Schultze-Mosgau MH; Engelen A; Piel I; Denner K; Roffel A; Tiessen R; Klein S; Francke K; Rottmann A
Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):71-85. PubMed ID: 38044419
[TBL] [Abstract][Full Text] [Related]
11. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
[TBL] [Abstract][Full Text] [Related]
12. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of iruplinalkib (WX‑0593) on non‑small cell lung cancer with
Zhang Q; Lv J; Li X; Zhang H; Zhu C; Wang M; Si M; Hu Y; Zhang S
Exp Ther Med; 2024 Feb; 27(2):53. PubMed ID: 38234623
[TBL] [Abstract][Full Text] [Related]
14. Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [
Guo F; Liu B; Li X; Wang H; Zhu X; Su Y; He C; Zhu M; Ding J; Xu Y; Zhao X; Wang Y; Shan R; Zhu J; Xie J; Ge Q; Fan L; Ding Y; Xie Y; Zhang C; Li H; Wang H; Zhou H
Cancer Chemother Pharmacol; 2023 Feb; 91(2):143-156. PubMed ID: 36572783
[TBL] [Abstract][Full Text] [Related]
15. Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects.
Johnson TR; Tan W; Goulet L; Smith EB; Yamazaki S; Walker GS; O'Gorman MT; Bedarida G; Zou HY; Christensen JG; Nguyen LN; Shen Z; Dalvie D; Bello A; Smith BJ
Xenobiotica; 2015 Jan; 45(1):45-59. PubMed ID: 25034009
[TBL] [Abstract][Full Text] [Related]
16. Metabolic disposition of [
Wang L; Guo L; Wang Y; Guo R; Xu Z; Gao Z; Xie L; Chen J; Chen Y; Liu Y; Zhang H; Bao L; Xu W; Zhu M; Shao F; Shu Y
Br J Clin Pharmacol; 2021 Mar; 87(3):1475-1485. PubMed ID: 32959915
[TBL] [Abstract][Full Text] [Related]
17. Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants.
Scheible H; Dyroff M; Seithel-Keuth A; Harrison-Moench E; Mammasse N; Port A; Bachmann A; Dong J; van Lier JJ; Tracewell W; Mitchell D
Clin Transl Sci; 2021 Nov; 14(6):2420-2430. PubMed ID: 34374206
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
Martin P; Oliver S; Kennedy SJ; Partridge E; Hutchison M; Clarke D; Giles P
Clin Ther; 2012 Jan; 34(1):221-37. PubMed ID: 22206795
[TBL] [Abstract][Full Text] [Related]
19. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
20. Absorption, metabolism, excretion, and safety of [
Zhou C; Xie L; Liu W; Zhang L; Zhou S; Wang L; Chen J; Li H; Zhao Y; Zhu B; Ding S; Zhang C; Shao F
Ann Transl Med; 2021 May; 9(10):867. PubMed ID: 34164501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
